5 Key Biopharma Movers From Last Week

Health and Healthcare

Published: March 27, 2016 10:25 am

Last Updated: January 13, 2020 11:30 am

Over the past week, a few biotech companies made impressive runs. These moves were the result of clinical trial results, U.S. Food and Drug Administration (FDA) decisions and more. The companies 24/7 Wall St. has picked stood out from the rest with positive news guiding them last week. We have included information about each company, as well as recent trading activity and the consensus price target.

Advaxis

Advaxis Inc. (NASDAQ: ADXS) announced that data from a dose-escalation study of ADXS-HER2 in canine osteosarcoma was published online March 18, 2016, in Clinical Cancer Research, a journal of the American Association for Cancer Research.

This treatment with ADXS-HER2 reduced the incidence of metastatic disease and prolonged survival relative to a historical control group. The median survival time for the ADXS-HER2 treated dogs was 956 days, which was significantly longer than the 423-day median survival time of the historical control group.

Osteosarcoma is the most common primary bone tumor in dogs, with over 10,000 dogs annually diagnosed. It is also the most common bone cancer in children and teens, and the third most common cancer in teens after lymphomas and brain tumors.

Shares of Advaxis rose 26% over the course of the week to a high of $10.39 but slid back down by the end of the week. Year to date, the shares are down around 15%. The stock closed most recently at $8.74. The consensus price target is $24.17, and the 52-week range is $5.21 to $30.13.